<DOC>
	<DOCNO>NCT00577720</DOCNO>
	<brief_summary>To compare efficacy 50 mg delayed-release risedronate tablet , dose immediately breakfast , 35 mg immediate-release tablet , administer accord label instruction .</brief_summary>
	<brief_title>Assess Safety , Efficacy , Pharmacokinetics Immediate Delayed Release Weekly Risedronate</brief_title>
	<detailed_description>To compare efficacy , base bone turnover marker ( BTM ) serum Type I collagen C-telopeptide ( CTx ) , 50 mg delayed-release risedronate tablet , administer immediately typical breakfast , 35 mg immediate-release tablet , administer accord label instruction ( ie , least 30 minute prior breakfast ) postmenopausal woman 13 week treatment .</detailed_description>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>In generally good health , determine medical history , physical examination , laboratory test result Postmenopausal great 2 year , naturally surgically base medical history . Used follow medication within 3 month prior dose use follow medication 1 month time within 6 month prior dose : oral parenteral glucocorticoid ( 5 mg prednisone equivalent/day ) anabolic steroid estrogen ( oral , skin patch , gel ) , except low dose vaginal product insertable estrogen ring , selective estrogenreceptor modulators , estrogenrelated drug progestin calcitonin vitamin D supplement calcitriol , calcidiol , alfacalcidol dose bisphosphonate fluoride strontium parathyroid hormone , include teriparatide</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>